Drug-drug interactions: Designing development programs and appropriate product labeling

Pharmacokinetics in Drug Development

Volumn 3, Issue , 2011, Pages 21-56

  Hutzler, J Matthew ^a   Cook, Jack ^b   Fleishaker, Joseph C ^b  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900120381     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-7937-7_2     Document Type: Chapter

References (144)

1. Anglicheau D, Legendre C, Beaune P, and Thervet E. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics 2007;8:835-849.
2. Aninat C, Piton A, Glaise D, Le CT, Langouet S, Morel F, Guguen-Guillouzo C, and Guillouzo A. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 2006;34:75-83.
3. Bakken GV, Rudberg I, Christensen H, Molden E, Refsum H, and Hermann M. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Metab Dispos 2009;37:254-258.
4. Becker ML, Kallewaard M, Caspers PWJ, Visser LE, Leufkens HGM, and Strick BHC. Hospitalisations and emergency department visits dues to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf 2007;16:641-651.
5. Bell L, Bickford S, Nguye PH, Wang J, He T, Zhang B, Friche Y, Zimmerlin A, Urban L, and Bojanic D. Evaluation of fluorescence- and mass spectrometrybased CYP inhibition assays for use in drug discovery. J Biomol Screen 2008;13:343-353.
6. Benet LZ and Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002;71:115-121.
7. Berry LM and Zhao Z. An examination of IC50 and IC50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes. Drug Metab Lett 2008;2:51-59.
8. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Backman M, Ohlsson R, Postlind H, Blomquist P, and Berkenstam A. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A 1998;5:12208-12213.
9. Burchell B, Soars M, Monaghan G, Cassidy A, Smith D, and Ethell B. Drug-mediated toxicity caused by genetic deficiency of UDP- glucuronosyltransferases. Toxicol Lett 2000;112-113:333-340.
10. Cali JJ, Ma D, Sobol M, Simpson DJ, Frackman S, Good TD, Daily WJ, and Liu D. Luminogenic cytochrome P450 assays. Expert Opin Drug Metab Toxicol 2006;2:629-645.
11. Cawley GF, Batie CJ, and Backes WL. Substratedependent competition of different P450 isozymes for limiting NADPH-cytochrome P450 reductase. Biochemistry 1995;34:1244-1247.
12. Chen Q, Ngui JS, Doss GA, Wang RW, Cai X, DiNinno FP, Blizzard TA, Hammond ML, Stearns RA, Evans DC, Baillie TA, and Tang W. Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem Res Toxicol 2002;15:907-914.
13. 50) of an enzymatic reaction. Biochem Pharmacol 1973;23:3099-3108.
14. Chu V, Einolf HJ, Evers R, Kumar G, Moore D, Ripp S, Silva J, Sinha V, Sinz M, and Skerjanec A. In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of America perspective. Drug Metab Dispos 2009;37:1339-1354.
15. Cohen LH, Remley MJ, Raunig D, and Vaz ADN. In vitro drug interactions of cytochrome P450: an evaluation of fluorogenic to conventional substrates. Drug Metab Dispos 2003;31:1005-1015.
16. 50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies. Mol Pharm 2010; Apr. 5;7(2):398-411.
17. Crespi CL and Stresser DM. Flurometric screening for metabolism-based drug-drug interactions. J Pharmacol Toxicol Methods 2000;44:325-331.
18. Cui X, Thomas A, Gerlach V, White RE, Morrison RA, and Cheng KC. Application and interpretation of hPXR screening data: validation of reporter signal requirements for prediction of clinically relevant CYP3A4 inducers. Biochem Pharmacol 2008;76:680-689.
19. Dalvie D, Kang P, Zientek M, Xiang C, Zhou S, and Obach RS. Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats. Chem Res Toxicol 2008;21:2260-2271.
20. Dixit V, Haraparsad N, Desai P, and Unadkat JD. In vitro LC-MS cocktail assays to simultaneously determine human cytochrome P450 activities. Biopharm Drug Dispos 2007;28:257-262.
21. Duan JZ. Applications of population pharmacokinetics in current drug labelling. J Clin Pharm Ther 2007;32:57-79.
22. El-Sankary W, Gibson GG, Ayrton A, and Plant N. Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab Dispos 2001;29:1499-1504.
23. Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, and Nettleton D. A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 2008;36:1698-1708.
24. Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, and de Morais SM. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos 2008;36:268-275.
25. Feng B, Xu JJ, Bi YA, Mireles R, Davidson R, Duignan DB, Campbell S, Kostrubsky VE, Dunn MC, Smith AR, and Wang HF. Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724, 714. Toxicol Sci 2009;108:492-500.
26. Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA, and Lee CA. Drug-drug mediated interactions mediated through p-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 2009;85:173-181.
27. Fontana E, Dansette PM, and Poli SM. Cytochrome p450 enzymes mechanism based inhibitors: common substructures and reactivity. Curr Drug Metab 2005;6:413-454.
28. Foti RS and Wahlstrom JL. Prediction of CYP-mediated drug interactions in vivo using in vitro data. IDrugs 2008;11:900-905.
29. Fromm MF, Kim RB, Stein CM, Wilkinson GR, and Roden DM. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine [see comments]. Circulation 1999;99:552-557.
30. Galetin A, Burt H, Gibbons L, and Houston JB. Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 2006;34:166-175.
31. Galetin A, Hinton LK, Burt H, Obach RS, and Houston JB. Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. Curr Drug Metab 2007;8:685-693.
32. Galetin A, Gertz M, and Houston JB. Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions. Expert Opin Drug Metab Toxicol 2008;4:909-922.
33. Gao F, Johnson DL, Ekins S, Janiszewski J, Kelly KG, Meyer RD, and West M. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC (50). J Biomol Screen 2002;7:373-382.
34. Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT, and Rostami-Hodjegan A. A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr Drug Metab 2006;7:315-334.
35. Grim KH, Bird J, Ferguson D, and Riley RJ. Mechanismbased inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. Eur J Pharm Sci 2009;36:175-191.
36. Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, Ling KH, Lu C, Nomeir AA, Seibert E, Skordos KW, Tonn GR, Van HR, Wang RW, Wong YN, Yang TJ, and Obach RS. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 2009;37:1355-1370.
37. Guengerich FP. Update information on human P550s. Drug Metab Rev 2002;34:7-15.
38. Guengerich FP. Cytochrome P450 and chemical toxicity. Chem Res Toxicol 2008;21:70-83.
39. Hager WD, Fenster P, Mayersohn M, Perrier D, Graves P, Marcus FI, and Goldman S. Digoxin-quinidine interaction pharmacokinetic evaluation. N Engl J Med 1979;300(22):1238-1241.
40. Hamelin BA, Bouayad A, Methot J, Jobin J, Desgagnes P, Poirier P, Allaire J, Dumesnil J, and Turgeon J. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther 2000;67:466-477.
41. Hariparsad N, Carr BA, Evers R, and Chu X. Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. Drug Metab Dispos 2008;36:1046-1055.
42. Harmsen S, Koster AS, Beijnen JH, Schellens JH, and Meijerman I. Comparison of two immortalized human cell lines to study nuclear receptor-mediated CYP3A4 induction. Drug Metab Dispos 2008;36:1166-1171.
43. Hebert MF, Roberts JP, Prueksaritanont T, and Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992;52:453-457.
44. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, and van Gelder T. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003;74:245-254.
45. Hesselink DA, van Schaik RHN, van Agteren M, de Fijter JW, Hartmann A, Zeier M, Budde K, Kuypers DR, Pisarski P, Meur YL, Mamelok RD, and van Gelder T. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics 2008;18:339-348.
46. Hollenberg PF, Kent UM, and Bumpus NN. Mechanismbased inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications. Chem Res Toxicol 2008;21:189-205.
47. Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994;47:1469-1479.
48. Huang W, Lin YS, McConn DJ, Calamia JC, Totah RA, Isoherranen N, Glodowski M, and Thummel KE. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 2004;32:1434-1445.
49. Hutzler JM, Melton RJ, Rumsey JM, Schnute ME, Locuson CW, and Wienkers LC. Inhibition of cytochrome P450 3A4 by a pyrimidineimidazole: evidence for complex heme interactions. Chem Res Toxicol 2006;19:1650-1659.
50. Ismail R and Teh LK. The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients. J Clin Pharm Ther 2006;31:99-109.
51. ® population-based ADME simulator. Expert Opin Drug Metab Toxicol 2009;5:211-223.
52. Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, and Hall SD. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 1999;290:1116-1125.
53. Jones SA, Moore LB, Wisely GB, and Kliewer SA. Use of in vitro pregnane X receptor assays to assess CYP3A4 induction potential of drug candidates. Methods Enzymol 2002;357:161-170.
54. Kalgutkar AS, Obach RS, and Maurer TS. Mechanismbased inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab 2007;8:407-447.
55. Kanamitsu S, Ito K, and Sugiyama Y. Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res 2000;17:336-343.
56. Kanebratt KP and Andersson TB. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos 2008;36:137-145.
57. Kawahara I, Kato Y, Suzuki H, Achira M, Ito K, Crespi CL, and Sugiyama Y. Selective inhibition of human cytochrome P450 3A4 by N-[2 (R)-hydroxy-1 (S) - indanyl]-5-[2 (S) - (1, 1-dimethylethylaminocarbonyl) - 4-[(furo[2, 3-b]pyridin-5-yl) methyl]piperazin-1-yl]-4 (S)-hydroxy-2 (R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems. Drug Metab Dispos 2000;28:1238-1243.
58. Kenny JR, Chen L, McGinnity DF, Grime K, Shakesheff KM, Thomson B, and Riley R. Efficient assessment of the utility of immortalized Fa2N-4 cells for cytochrome P450 (CYP) induction studies using multiplex quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and substrate cassette methodologies. Xenobiotica 2008;38:1500-1517.
59. Kim M-J, Kim H, Cha I-J, Park J-S, Shon J-H, Liu K-H, and Shin J-G. High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2005;19:2651-2658.
60. Kindla J, Fromm MF, and Konig J. In vitro evidence for the role of OATP and OCT uptake transporters in drug-drug interactions. Expert Opin Drug Metab Toxicol 2009;5:489-500.
61. Klotz T, Sachse R, Heidrich A, Jockenhovel F, Rohde G, Wensing G, Horstmann R, and Engelmann R. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 2001;19:32-39.
62. Kongkaew C, Noyce PR, and Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother 2008;42:1017-1025.
63. Kostrubsky SE, Strom SC, Kalgutkar AS, Kulkarni S, Atherton J, Mireles R, Feng B, Kubik R, Hanson J, Urda E, and Mutlib AE. Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol Sci 2006;90:451-459.
64. Kovarik JM, Rigaudy L, Guerret M, Gerbeau C, and Rost KL. Longitudinal assessment of a P-glycoproteinmediated drug interaction of valspodar on digoxin. Clin Pharmacol Ther 1999;66:391-400.
65. Krayenbuhl JC, Vozeh S, Kondo-Oestreicher M, and Dayer P. Drug-drug interactions of the new active substances: mibefradil example. Eur J Clin Pharmacol 1999;55:559-565.
66. Ku HY, Ahn HJ, Seo KA, Kim H, Oh M, Bae SK, Shin JG, Shon JH, and Liu KH. The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos 2008;36:986-990.
67. Kumar V, Wahlstrom JL, Rock DA, Warren CJ, Gorman LA, and Tracy TS. CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos 2006;34:1966-1975.
68. Kumar V, Brundage RC, Oetting WS, Leppik IE, and Tracy TS. Differential genotype dependent inhibition of CYP2C9 in humans. Drug Metab Dispos 2008;36:1242-1248.
69. LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, and Narang PK. Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone. J Clin Pharmacol 1998;38:1042-1050.
70. Lecoeur S, Bonierbale E, Challine D, Gautier JC, Valadon P, Dansette PM, Catinot R, Ballet F, Mansuy D, and Beaune PH. Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs. Chem Res Toxicol 1994;7:434-442.
71. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, and Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998;102:1016-1023.
72. Lessard E, Yessine MA, Hamelin BA, Gauvin C, Labbe L, O'Hara G, LeBlanc J, and Turgeon J. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. J Clin Psychopharmacol 2001;21:175-184.
73. Lin JH. CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm Res 2006;23:1089-1116.
74. Linder CD, Renaud NA, and Hutzler JM. Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos 2009;37:10-13.
75. Lopez-Garcia MP, Dansette PM, and Mansuy D. Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. Biochemistry 1994;33:166-175.
76. Lu P, Schrag ML, Slaughtetr DE, Raab CE, Shou M, and Rodrigues AD. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos 2003;31:1352-1360.
77. Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S, Gilbert D, Downey A, Mudra D, Graham R, Carroll K, Xie J, Madan A, Parkinson A, Christ D, Selling B, LeCluyse E, and Gan LS. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002;30:795-804.
78. Luo G, Guenthner T, Gan LS, and Humphreys WG. CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development. Curr Drug Metab 2004;5:483-505.
79. Mayhew BS, Jones DR, and Hall SD. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 2000;28:1031-1037.
80. McDonnell PJ and Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002;36:1331-1336.
81. McGinnity DF, Berry AJ, Kenny JR, Grime K, and Riley RJ. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab Dispos 2006;34:1291-1300.
82. McGinnity DF, Zhang G, Kenny JR, Hamilton GA, Otmani S, Stams KR, Haney S, Brassil P, Stresser DM, and Riley RJ. Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells. Drug Metab Dispos 2009;37:1259-1268.
83. Miller VP, Stresser DM, Blanchard AP, Turner S, and Crespi CL. Fluorometric high-throughput screening for inhibitors of cytochrome P450. Ann NY Acad Sci 2000;919:26-32.
84. Mills JB, Rose KA, Sadagopan N, Sahi J, and de Morais SM. Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J Pharmacol Exp Ther 2004;309:303-309.
85. Neuvonen PJ, Niemi M, and Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565-581.
86. Obach RS. Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances. Curr Opin Drug Discov Devel 2009;12:81-89.
87. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 2006;316:336-348.
88. Obach RS, Walsky RL, and Venkatakrishnan K. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 2007;35:246-255.
89. Olinga P, Elferink MG, Draaisma AL, Merema MT, Castell JV, Perez G, and Groothuis GM. Coordinated induction of drug transporters and phase I and II metabolism in human liver slices. Eur J Pharm Sci 2008;33:380-389.
90. Ortiz de Montellano PR, ed. Cytochrome P450: Structure, metabolism, and biochemistry, 3rd ed. Klower Academic/Plenum Publishers, New York, 2005.
91. Pearson JT, Wahlstrom JL, Dickmann LJ, Kumar S, Halpert JR, Wienkers LC, Foti RS, and Rock DA. Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates. Chem Res Toxicol 2007;20:1778-1786.
92. Plumb RS, Potts WB, III, Rainville PD, Alden PG, Shave DH, Baynham G, and Mazzeo JR. Addressing the analytical throughput challenges in ADME screening using rapid ultra-performance liquid chromatography/tandem mass spectrometry methodologies. Rapid Commun Mass Spectrom 2008;22:2139-2152.
93. Proctor NJ, Tucker GT, and Rostami-Hodjegan A. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 2004;34:151-178.
94. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, and Harris JW. Selective biotransformation of taxol to 6-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994;54:5543-5546.
95. Rajagopalan P, Mazzu A, Xia C, Dawkins R, and Sundaresan P. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 2003;43(3):260-267.
96. Ripp SL, Mills JB, Fahmi OA, Trevena KA, Liras JL, Maurer TS, and de Morais SM. Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab Dispos 2006;34:1742-1748.
97. Rock DA, Foti RS, and Pearson JT. The combination of chemical and antibody inhibitors for superior P450 3A inhibition in reaction phenotyping studies. Drug Metab Dispos 2008;36:2410-2413.
98. Rostami-Hodjegan A and Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 2007;6:140-148.
99. Rowland M and Martin SB. Kinetics of drug-drug interactions. J Pharmacokinet Biopharm 1973;1:553-567.
100. Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, and Miners JO. Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther 2007;321:137-147.
101. Roymans D, Annaert P, Van HJ, Weygers A, Noukens J, Sensenhauser C, Silva J, Van LC, Hendrickx J, Mannens G, and Meuldermans W. Expression and induction potential of cytochromes P450 in human cryopreserved hepatocytes. Drug Metab Dispos 2005;33:1004-1016.
102. Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, and Johnson EF. Structure of human microsomal cytochrome P450 2C8. JBiol Chem 2004;279:9497-9503.
103. Seithel A, Eberl S, Singer K, Auge D, Heinkele G, Wolf NB, Dorje F, Fromm MF, and Konig J. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos 2007;35:779-786.
104. Shen DD, Kunze KL, and Thummel KE. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev 1997;27:99-127.
105. Shirasaka Y, Sakane T, and Yamashita S. Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J Pharm Sci 2008;97:553-565.
106. Silverman RB and George C. Mechanism of inactivation of gamma-aminobutyric acid aminotransferase by (S, E)-4-amino-5-fluoropent-2-enoic acid. Biochem Biophys Res Commun 1988;150(3):942-946.
107. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, and Schneck DW. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004;76:167-177.
108. Sinz M, Kim S, Zhu Z, Chen T, Anthony M, Dickinson K, and Rodrigues AD. Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 2006;7:375-388.
109. Smith DA. Induction and drug development. Eur J Pharm Sci 2000;11:185-189.
110. Smith DA and Schmid EF. Drug withdrawals and the lessons within. Curr Opin Drug Discov Devel 2006;9:38-46.
111. Taipalensuu J, Tornblom H, Lindberg G, Einarsson C, Sjoqvist F, Melhus H, Garberg P, Sjostrom B, Lundgren B, and Artursson P. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 2001;299:164-170.
112. Tamai I. Intestinal and Hepatic Transport and Metabolism: Role of Transporters in Drug Absorption. Presentation at Strategies in Oral Drug Delivery 2009. Garmisch, Germany, March 8-13, 2009.
113. Tang C, Shou M, Rushmore TH, Mei Q, Sandhu P, Woolf EJ, Rose MJ, Gelmann A, Greenberg HE, De Lepeleire I, Van Hecken A, De Schepper PJ, Ebel DL, Schwartz JI, and Rodrigues AD. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics 2001;11:223-235.
114. Testino SA and Patonay G. High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2003;30:1459-1467.
115. Tiberghien F and Loor F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs 1996;7:568-578.
116. Tomalik-Scharte D, Lazar A, Fuhr U, and Kirchheiner J. The clinical role of genetic polymorphisms in drugmetabolizing enzymes. Pharmacogenomics J 2008;8:4-15.
117. Treiber A, Schneiter R, Hausler S, and Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as a common mechanism of its interactions with cyclosporin A, rifampicin and sildenafil. Drug Metab Dispos 2007;35:1400-1407.
118. Uno T, Shimizu M, Yasui-Furukori N, Sugawara K, and Tateishi T. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. Br J Clin Pharmacol 2006;61:309-314.
119. Van den Berg HW, Desai ZR, Wilson R, Kennedy G, Bridges JM, and Shanks RG. The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol 1982;8:215-219.
120. Van LM, Heydari A, Yang J, Hargreaves J, Rowland-Yeo K, Lennard MS, Tucker GT, and Rostami-Hodjegan A. The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy). J Psychopharmacol 2006;20:834-841.
121. Venkatakrishnan K, von Moltke LL, Court MH, Harmatz JS, Crespi CL, and Greenblatt DJ. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 2000;28:1493-1504.
122. Walsky RL and Obach RS. Validated assays for human cytochrome P450 activities. Drug Metab Dispos 2004;32:647-660.
123. Walsky RL, Gaman EA, and Obach RS. Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 2005;45:68-78.
124. Walsky RL, Astuccio AV, and Obach RS. Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol 2006;46:1426-1438.
125. Wang RW, Newton DJ, Liu N, Atkins WM, and Lu AY. Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 2000;28:360-366.
126. Wang JH, Liu ZQ, Wang W, Chen XP, Shu Y, He N, and Zhou HH. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001;70:42-47.
127. Wang YH, Jones DR, and Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 2004;32:259-266.
128. Watanabe A, Nakamura K, Okudaira N, Okazaki O, and Sudo K. Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. Drug Metab Dispos 2007;35:1232-1238.
129. Wienkers LC and Heath TG. Predicting in vivo drug interactions from in vitro discovery data. Nat Rev Drug Discov 2005;4:825-833.
130. Wienkers LC and Stevens JC. Cytochrome P450 reaction phenotyping. In: Drug metabolizing enzymes: Cytochrome P450 and other enzymes in drug discovery and development. Edited by Lee JA, Obach RS, and Fisher MB. CRC Press, Boca Raton, 2003, pp. 255-310.
131. Williams JA, Hurst SI, Bauman J, Jones BC, Hyland R, Gibbs JP, Obach RS, and Ball SE. Reaction phenotyping in drug discovery: moving forward with confidence? Curr Drug Metab 2003;4:527-534.
132. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, and Ball SE. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 2004;32:1201-1208.
133. Wrighton SA and Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
134. Wu CY and Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005;22:11-23.
135. Xie HG, Wood AJ, Kim RB, Stein CM, and Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004;5:243-272.
136. Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A. Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 2008;9:384-394.
137. Youdim KA, Lyons R, Payne L, Jones BC, and Saunders K. An automated, high-throughput, 384 well Cytochrome P450 cocktail IC50 assay using a rapid resolution LC-MS/MS end-point. J Pharm Biomed Anal 2008;48:92-99.
138. Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, and Schwab M. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 2007;8:743-759.
139. Zhang H, Davis CD, Sinz MW, and Rodrigues AD. Cytochrome P450 reaction-phenotyping: an industrial perspective. Expert Opin Drug Metab Toxicol 2007;3:667-687.
140. Zhang L, Zhang YD, Strong JM, Reynolds KS, and Huang SM. A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 2008;38:709-724.
141. Zhao P. The use of hepatocytes in evaluating timedependent inactivation of P450 in vivo. Expert Opin Drug Metab Toxicol 2008;4:151-164.
142. Zhao P, Kunze KL, and Lee CA. Evaluation of timedependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metab Dispos 2005;33:853-861.
143. Zhou S, Chan E, Lim LY, Boelsterli UA, Li SC, Wang J, Zhang Q, Huang M, and Xu A. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 2004;5:415-442.
144. Zientek M, Miller H, Smith D, Dunklee MB, Heinle L, Thurston A, Lee C, Hyland R, Fahmi O, and Burdette D. Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds. J Pharmacol Toxicol Methods 2008;58:206-214.